Clinical practice guidelines on antiemetics in oncology. (Q36334870)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

review article

1 reference

title

Clinical practice guidelines on antiemetics in oncology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Enrique Aranda Aguilar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Manuel Constenla Figueiras

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Hernán Cortes-Funes

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Pere Gascon Vilaplana

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Vicente Guillém

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Salvador Martin-Algarra

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 December 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

10 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

963-972

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

Drug treatment of chemotherapy-induced delayed emesis

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Control of chemotherapy-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

5-HT3 receptor antagonists for prevention of late acute-onset emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Ondansetron Clinical Pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Potential of substance P antagonists as antiemetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.963

21 January 2018

Identifiers

DOI

10.1586/14737140.5.6.963

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16336087%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference